SEC Form 4 · accession 0000899243-18-016599
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Bjerkholt
Officer — Chief Financial Officer
Period of report
Jun 13, 2018
Accepted (ET)
Jun 14, 2018 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1,F2,F3 | Jun 13, 2018 | P | 1,600 | $30.4144 | A | 19,485 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction was executed in multiple trades in prices ranging from $30.35 to $30.4292, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- F2Includes shares represented by restricted stock units ("RSUs") and will be settled in common stock upon vesting over a specified time, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- F3Includes 385 shares acquired on May 15, 2018 pursuant to Issuer's employee stock purchase plan.